Boosting vaccinations with peptide-pulsed CD34+ progenitor-derived dendritic cells can expand long-lived melanoma peptide-specific CD8+ T cells in patients with metastatic melanoma

A. Karolina Palucka, Madhav V. Dhodapkar, Sophie Paczesny, Hideki Ueno, Joseph Fay, Jacques Banchereau

Research output: Contribution to journalArticle

30 Scopus citations


The immunogenicity of dendritic cell (DC)-based vaccines has been shown in patients with advanced cancer, but it has not yet been established whether the elicited cancer-specific immunity is durable and whether it can be maintained by boosting vaccinations. The authors showed earlier, in 18 HLA-A*0201 metastatic melanoma patients, that four vaccinations over 6 weeks with peptide-loaded CD34-DCs (the induction phase) expand in the blood melanoma-specific CD8+ T cells, as documented by melanoma peptide-specific IFN-γ ELISPOT and cytotoxic T-lymphocyte (CTL) activity against melanoma cell lines. The authors show here that the melanoma peptide-specific CD8+ T-cell immunity is short-lived, but it could be reactivated in 7 of 11 patients who received four boosting vaccinations with peptide-loaded CD34-DCs. Expansion of recall memory CD8+ T cells was confirmed by tetramer binding and CTL activity against melanoma peptide-pulsed T2 cells. In two patients boosted over 15 months, induced melanoma peptide-specific recall memory CD8+ T cells lasted at least 6 months. Thus, boosting vaccination with peptide-loaded CD34-DCs can expand long-lived tumor peptide-specific immunity.

Original languageEnglish (US)
Pages (from-to)158-168
Number of pages11
JournalJournal of Immunotherapy
Issue number2
StatePublished - 2005


  • CD8T-cell immunity
  • Cytokines
  • Tumor immunity
  • Tumor vaccines

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Cancer Research

Fingerprint Dive into the research topics of 'Boosting vaccinations with peptide-pulsed CD34<sup>+</sup> progenitor-derived dendritic cells can expand long-lived melanoma peptide-specific CD8<sup>+</sup> T cells in patients with metastatic melanoma'. Together they form a unique fingerprint.

  • Cite this